Riegel v. Medtronic, Inc. | |
---|---|
Argued December 4, 2007 Decided February 20, 2008 | |
Full case name | Charles R. Riegel, et ux. v. Medtronic, Inc. |
Docket no. | 06-179 |
Citations | 552 U.S. 312 ( more ) 128 S. Ct. 999; 169 L. Ed. 2d 892 |
Argument | Oral argument |
Holding | |
The MDA's pre-emption clause bars common-law claims challenging the safety or effectiveness of a medical device marketed in a form that received premarket approval from the FDA. | |
Court membership | |
| |
Case opinions | |
Majority | Scalia, joined by Roberts, Kennedy, Souter, Thomas, Breyer, Alito; Stevens (except Parts III–A and III–B) |
Concurrence | Stevens (in part) |
Dissent | Ginsburg |
Riegel v. Medtronic, Inc., 552 U.S. 312 (2008), is a United States Supreme Court case in which the Court held that the pre-emption clause of the Medical Device Amendment bars state common-law claims that challenge the effectiveness or safety of a medical device marketed in a form that received premarket approval from the Food and Drug Administration. [1]
It modified the rule in Medtronic, Inc. v. Lohr . [2]
Intel Corp. v. Advanced Micro Devices, Inc., 542 U.S. 241 (2004), is a decision by the Supreme Court of the United States involving 28 U.S.C. § 1782, which authorizes United States district courts to enforce discovery requests made in connection with litigation being conducted in foreign tribunals. Prior to Intel, there had been substantial disagreement as to the availability of Section 1782 discovery.
Medtronic plc is an American medical device company. The company's operational and executive headquarters are in Minneapolis, Minnesota, and its legal headquarters are in Ireland due to its acquisition of Irish-based Covidien in 2015. While it primarily operates in the United States, it operates in more than 150 countries and employs over 90,000 people. It develops and manufactures healthcare technologies and therapies.
Railroad Commission v. Pullman Co., 312 U.S. 496 (1941), was a case in which the United States Supreme Court determined that it was appropriate for United States federal courts to abstain from hearing a case in order to allow state courts to decide substantial Constitutional issues that touch upon sensitive areas of state social policy.
Eli Lilly and Company v. Medtronic, Inc., 496 U.S. 661 (1990), is a United States Supreme Court case related to patent infringement in the medical device industry. It held that 35 U.S.C. § 271(e)(1) of United States patent law exempted premarketing activity conducted to gain approval of a device under the Federal Food, Drug, and Cosmetic Act from a finding of infringement.
The 2007 term of the Supreme Court of the United States began October 1, 2007, and concluded September 30, 2008. The table illustrates which opinion was filed by each justice in each case and which justices joined each opinion.
The Supreme Court of the United States handed down six per curiam opinions during its 2007 term, which began October 1, 2007 and concluded September 30, 2008.
Medellín v. Texas, 552 U.S. 491 (2008), was a decision of the United States Supreme Court that held that even when a treaty constitutes an international commitment, it is not binding domestic law unless it has been implemented by an act of the U.S. Congress or contains language expressing that it is "self-executing" upon ratification. The Court also ruled that decisions of the International Court of Justice are not binding upon the U.S. and, like treaties, cannot be enforced by the president without authority from Congress or the U.S. Constitution.
FDA preemption is the legal theory in the United States that exempts product manufacturers from tort claims regarding products approved by the Food and Drug Administration (FDA). It has been a highly-contentious issue. In general, consumer groups are against it, but the FDA and pharmaceutical manufacturers are in favor of it and argues that the FDA should set both the floor and the ceiling for drug regulation.
Altria Group v. Good, 555 U.S. 70 (2008), was a United States Supreme Court case in which the Court held that a state law prohibiting deceptive tobacco advertising was not preempted by a federal law regulating cigarette advertising.
Wyeth v. Levine, 555 U.S. 555 (2009), is a United States Supreme Court case holding that Federal regulatory approval of a medication does not shield the manufacturer from liability under state law.
Quanta Computer, Inc. v. LG Electronics, Inc., 553 U.S. 617 (2008), is a case decided by the United States Supreme Court in which the Court reaffirmed the validity of the patent exhaustion doctrine. The decision made uncertain the continuing precedential value of a line of decisions in the Federal Circuit that had sought to limit Supreme Court exhaustion doctrine decisions to their facts and to require a so-called "rule of reason" analysis of all post-sale restrictions other than tie-ins and price fixes. In the course of restating the patent exhaustion doctrine, the Court held that it is triggered by, among other things, an authorized sale of a component when the only reasonable and intended use of the component is to engage the patent and the component substantially embodies the patented invention by embodying its essential features. The Court also overturned, in passing, that the exhaustion doctrine was limited to product claims and did not apply to method claims.
The exhausted combination doctrine, also referred to as the doctrine of theLincoln Engineeringcase, is the doctrine of U.S. patent law that when an inventor invents a new, unobvious device and seeks to patent not merely the new device but also the combination of the new device with a known, conventional device with which the new device cooperates in the conventional and predictable way in which devices of those types have previously cooperated, the combination is unpatentable as an "exhausted combination" or "old combination". The doctrine is also termed the doctrine of the Lincoln Engineering case because the United States Supreme Court explained the doctrine in its decision in Lincoln Engineering Co. v. Stewart-Warner Corp.
In the law of the United States, federal preemption is the invalidation of a U.S. state law that conflicts with federal law.
Medtronic, Inc. v. Lohr, 518 U.S. 470 (1996), is a United States Supreme Court case dealing with the scope of federal preemption.
Hall Street Associates, L.L.C. v. Mattel, Inc., 552 U.S. 576 (2008), was a United States Supreme Court case that held that state and federal courts cannot, on a motion to vacate or to modify an arbitration award, expand the limited scope of judicial review specified in 9 U.S.C. §§ 10 and 11, including terms that were agreed upon by the parties.
Donald Cameron Findlay is an American attorney who is the senior vice president, general counsel, and secretary of Archer Daniels Midland Company, the global agriculture business giant ranked 28th on the Fortune 500 list of largest American companies. He joined ADM in 2013. Prior to that, he served from 2009 to 2013 as senior vice president, general counsel, and secretary of Medtronic, Inc., the world's largest medical device company. Before his time at Medtronic, he was executive vice president and general counsel for Aon Corporation for six years. Previously he served as Deputy Secretary of Labor from 2001 to 2003 in the administration of George W. Bush and as a member of the board of directors of the Overseas Private Investment Corporation. Prior to that, he was a partner in the law firm of Sidley Austin, where his practice focused on complex litigation and regulatory matters for companies in heavily regulated industries like telecommunications and energy. Before his time at Sidley, he served in the White House as a senior aide to President George H.W. Bush.
Sorrell v. IMS Health Inc., 564 U.S. 552 (2011), is a United States Supreme Court case in which the Court held that a Vermont statute that restricted the sale, disclosure, and use of records that revealed the prescribing practices of individual doctors violated the First Amendment.
Medtronic, Inc. v. Mirowski Family Ventures, LLC, 571 U.S. 191 (2014), is a case of the Supreme Court of the United States that deals with civil procedure, and specifically with the question of the burden of proof required in pursuing declaratory judgments.
Akamai Technologies, Inc. v. Limelight Networks, Inc., 797 F.3d 1020, is a 2015 en banc decision of the United States Court of Appeals for the Federal Circuit, on remand from a 2014 decision of the U.S. Supreme Court reversing a previous Federal Circuit decision in the case. This is the most recent in a string of decisions in the case that concern the proper legal standard for determining patent infringement liability when multiple actors are involved in carrying out the claimed infringement of a method patent and no single accused infringer has performed all of the steps. In the 2015 remand decision, the Federal Circuit expanded the scope of vicarious liability in such cases, holding that one actor could be held liable for the acts of another actor "when an alleged infringer conditions participation in an activity or receipt of a benefit upon performance of a step or steps of a patented method and establishes the manner or timing of that performance." In addition, the court held that where multiple "actors form a joint enterprise, all can be charged with the acts of the other[s], rendering each liable for the steps performed by the other[s] as if each is a single actor."